Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27624339 | 0.92 | ALDH1A1 (0.62) | KMT2ATDP1SLC6A2SLC6A3ALDH1A1 | |
| SCHEMBL31571742 | 0.84 | ALDH1A1 (0.63) | KMT2ATDP1ALDH1A1HPGDNPSR1 | |
| SCHEMBL11608575 | 0.84 | ALDH1A1 (0.57) | KMT2AALDH1A1HPGDNPSR1TSHR | |
| SCHEMBL179961 | 0.84 | ALDH1A1 (0.64) | KMT2ATDP1ALDH1A1HPGDNPSR1 | |
| SCHEMBL11039202 | 0.82 | ALDH1A1 (0.62) | KMT2AALDH1A1HPGDTSHRLMNA | |
| SCHEMBL7636627 | 0.82 | CES2 (0.57) | KMT2ATDP1SLC6A2SLC6A3ALDH1A1 | |
| SCHEMBL30452406 | 0.82 | ALDH1A1 (0.55) | KMT2ATDP1ALDH1A1HPGDNPSR1 | |
| SCHEMBL1532806 | 0.82 | ALDH1A1 (0.62) | KMT2ATDP1ALDH1A1HPGDNPSR1 | |
| SCHEMBL12175591 | 0.82 | ALDH1A1 (0.50) | KMT2AALDH1A1HPGDNPSR1TSHR | |
| SCHEMBL31757952 | 0.81 | KMT2A (0.66) | KMT2AALDH1A1HPGDTSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119930868-A | Catalyst component containing furoic acid ester compound, preparation method thereof, olefin polymerization catalyst, olefin polymerization method and olefin polymer | 中国石油化工股份有限公司 | 2025-05-06 | — | — | CN | claimed |
| WO-2001019185-A2 | METHODS FOR CONTROLLING A PEST POPULATION | SUMMUS GROUP, LTD. (US) | 2001-03-22 | — | — | WO | claimed |
| CN-115093355-B | Preparation method of pyrrole ester compound | 河南农业大学 | 2024-06-04 | — | — | CN | disclosed |
| CN-115093355-A | Preparation method of pyrrole ester compound | 河南农业大学 | 2022-09-23 | — | — | CN | disclosed |
| WO-2019002074-A1 | THIAZOLE COMPOUNDS USEFUL AS PRMT5 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2019-01-03 | — | — | WO | disclosed |
| CN-102822154-B | Heteroarylcarboxylicacid acid ester derivative | AJINOMOTO CO.,INC. (JP) | 2016-06-01 | — | — | CN | disclosed |
| US-9018259-B2 | Treatment of cancer using benzoic acid derivatives | NEW YORK UNIVERSITY (US) | 2015-04-28 | — | — | US | disclosed |
| CN-103254028-A | Method for synthesizing carboxylic acid by removing benzyl protection of benzyl carboxylate | UNIV CHONGQING | 2013-08-21 | — | — | CN | disclosed |
| US-20120329861-A1 | TREATMENT OF CANCER USING BENZOIC ACID DERIVATIVES | NEW YORK UNIVERSITY (US) | 2012-12-27 | — | — | US | disclosed |
| CN-102822154-A | Heteroarylcarboxylic acid ester derivative | AJINOMOTO KK | 2012-12-12 | — | — | CN | disclosed |
| US-4305872-A | HYPOTHALAMIC RELEASING AND INHIBITORY FACTORS, ENKEPHALINS AND ANTAGONISTS TO PRECURSOR PEPTIDES USEFUL IN BIOASSAY | Wingrove, Kenneth (US) | 1981-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329861-A1 | TREATMENT OF CANCER USING BENZOIC ACID DERIVATIVES | AHR, TYR, CYP4X1 | KMT2A 2450/4885TDP1 950/4885SLC6A2 928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.